In terms of the expression of adaptive immune resistance markers, CD8A, CD8B, immunomodulators [immunostimulants, major histocompatibility complex (MHC), receptors, and chemokines], immune-related pathways, and TIICs, compared with tumor tissues in the low B cell/DC1 infiltration group, most immune biomarkers were significantly upregulated in the high B cell group (LUAD) or high DC1 group (LUSC). This evidence concerns the gene CD8B and neoplasm.